US Capitol Capsule: Charting a new course for antibiotics
This article was originally published in Scrip
While the FDA last week again signaled it would like to see the process expedited for developing drugs to treat serious bacterial diseases in patients with unmet medical needs, including those infections for which currently available therapies do not respond, or drug-resistant bacteria – outlining approaches in a new guidance document for streamlining the development of those medicines – the agency, nonetheless, emphasized it was not creating any sort of a new pathway for approving those products. At least, not yet.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.